NewAmsterdam Pharma Company N.V.
Symbole: NAMS
NASDAQ
21.86
USDPrix du marché aujourd'hui
87.5675
Ratio P/E
0.0000
Ratio PEG
1.95B
Cap MRK
- 0.00%
Rendement DIV
NewAmsterdam Pharma Company N.V. (NAMS) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 340.4 | 438.5 | 53.1 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 1.9 | 1.9 | 4.3 | ||||
balance-sheet.row.inventory | 0 | -1.9 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 6.3 | 7.6 | 1.5 | ||||
balance-sheet.row.total-current-assets | 0 | 346.8 | 448.1 | 58.9 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0.2 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0.2 | 82.9 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.2 | 83.2 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0.1 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0.3 | 83.5 | 0.9 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.account-payables | 0 | 16.9 | 11.1 | 6.2 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 2.8 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0.1 | ||||
Deferred Revenue Non Current | 0 | 1 | 4.5 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 24 | 11.3 | 0 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 8.8 | 11.6 | 0.1 | ||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.total-liab | 0 | 58.7 | 47.1 | 10 | ||||
balance-sheet.row.preferred-stock | 0 | 317 | 0 | 0 | ||||
balance-sheet.row.common-stock | 0 | 10.2 | 599.2 | 83.9 | ||||
balance-sheet.row.retained-earnings | 0 | -317 | -119.4 | -34.7 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 4.4 | 4.7 | 0.6 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 273.8 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.net-debt | 0 | -340.4 | -438.4 | -52.9 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -176.9 | -78.1 | -28.6 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.1 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 5.2 | 0 | -1.4 | ||||
cash-flows.row.stock-based-compensation | 0 | 24.6 | 3.9 | 1 | ||||
cash-flows.row.change-in-working-capital | 0 | 5.9 | 11.5 | 3.8 | ||||
cash-flows.row.account-receivables | 0 | 3.7 | -3.9 | -4.6 | ||||
cash-flows.row.inventory | 0 | -3.7 | 5.9 | -0.1 | ||||
cash-flows.row.account-payables | 0 | 5.1 | -2 | 8.6 | ||||
cash-flows.row.other-working-capital | 0 | 0.8 | 11.5 | 0 | ||||
cash-flows.row.other-non-cash-items | 0 | 0 | 70.6 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 8.1 | 377.8 | 69 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.8 | -2.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 8.9 | 375.2 | 69 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5.1 | 1.6 | 1.4 | ||||
cash-flows.row.net-change-in-cash | 0 | -127.3 | 385.4 | 45.2 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 340.4 | 438.5 | 53.1 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 467.7 | 53.1 | 7.9 | ||||
cash-flows.row.operating-cash-flow | 0 | -141.2 | 8 | -25.2 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -141.2 | 8 | -25.2 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 14.1 | 97.5 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 14 | 97.4 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.cost-and-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.interest-income | 0 | 11.3 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 60.7 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -183 | -67.6 | -29.8 | ||||
income-statement-row.row.income-before-tax | 0 | -176.9 | -78.1 | -28.6 | ||||
income-statement-row.row.income-tax-expense | 0 | 0 | 70.8 | 0.2 | ||||
income-statement-row.row.net-income | 0 | -176.9 | -148.9 | -28.8 |
Questions fréquemment posées
Quel est le total de NewAmsterdam Pharma Company N.V. (NAMS) de l'actif total?
NewAmsterdam Pharma Company N.V. (NAMS) Le total des actifs est 347097000.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 1.000.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est -0.345.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.206.
Quel est le revenu total de l'entreprise?
Le revenu total est -0.335.
Qu'est-ce que NewAmsterdam Pharma Company N.V. (NAMS) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -176937000.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 60000.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 189195000.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.